- Home
- EDN vs COLL Comparison
EDN vs COLL Comparison
Compare EDN & COLL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EDN
- COLL
- Stock Information
- Founded
- EDN 1992
- COLL 2002
- Country
- EDN Argentina
- COLL United States
- Employees
- EDN N/A
- COLL N/A
- Industry
- EDN Electric Utilities: Central
- COLL Biotechnology: Pharmaceutical Preparations
- Sector
- EDN Utilities
- COLL Health Care
- Exchange
- EDN Nasdaq
- COLL Nasdaq
- Market Cap
- EDN 1.0B
- COLL 1.1B
- IPO Year
- EDN 2007
- COLL 2015
- Fundamental
- Price
- EDN $36.97
- COLL $30.10
- Analyst Decision
- EDN
- COLL Strong Buy
- Analyst Count
- EDN 0
- COLL 6
- Target Price
- EDN N/A
- COLL $42.00
- AVG Volume (30 Days)
- EDN 214.2K
- COLL 462.1K
- Earning Date
- EDN 12-03-2024
- COLL 11-07-2024
- Dividend Yield
- EDN N/A
- COLL N/A
- EPS Growth
- EDN N/A
- COLL 757.11
- EPS
- EDN 0.14
- COLL 2.16
- Revenue
- EDN $972,768,196.00
- COLL $599,245,000.00
- Revenue This Year
- EDN $144.81
- COLL $13.02
- Revenue Next Year
- EDN $81.78
- COLL $18.01
- P/E Ratio
- EDN $14.33
- COLL $13.87
- Revenue Growth
- EDN N/A
- COLL 9.62
- 52 Week Low
- EDN $13.78
- COLL $25.16
- 52 Week High
- EDN $37.98
- COLL $42.29
- Technical
- Relative Strength Index (RSI)
- EDN 77.07
- COLL 34.91
- Support Level
- EDN $29.30
- COLL $28.97
- Resistance Level
- EDN $37.98
- COLL $35.62
- Average True Range (ATR)
- EDN 1.93
- COLL 1.37
- MACD
- EDN 0.16
- COLL -0.13
- Stochastic Oscillator
- EDN 81.61
- COLL 21.65
About EDN Empresa Distribuidora Y Comercializadora Norte S.A. (Edenor)
Empresa Distribuidora y Comercializadora Norte SA is engaged in the distribution and sale of electricity. The firm's concession area covers the northern portion of the city of Buenos Aires mainly to residential, commercial, industrial, and public service.
About COLL Collegium Pharmaceutical Inc.
Collegium Pharmaceutical Inc is a specialty pharmaceutical company. The company is engaged in developing and planning to commercialize abuse-deterrent products that incorporate its patented DETERx platform technology for the treatment of chronic pain and other diseases. The DETERx platform technology is designed to maintain the extended-release and safety profiles of highly abused drugs in the face of various methods including chewing, crushing, and dissolving. Its product portfolio includes Xtampza ER, which is an abuse-deterrent, extended-release, oral formulation of oxycodone; and Nucynta Products, which are extended-release and immediate-release formulations of tapentadol; Belbuca, and Symproic.